Assessing GastroPanel serum markers as a non-invasive method for the diagnosis of atrophic gastritis and <i>Helicobacter pylori</i> infection
- 1 Yaounde Central Hospital, Faculty of Medicine and Pharmaceuticals Sciences, University of Douala, Douala, Cameroon
- 2 Faculty of Medicine and Biomedical Sciences, University of Yaounde, Yaounde, Cameroon
- 3 Douala General Hospital, Faculty of Medicine and Pharmaceuticals Sciences, University of Douala, Douala, Cameroon
- 4 District Hospital of Bonassama, Faculty of Medicine and Pharmaceuticals Sciences, University of Douala, Douala, Cameroon
- 5 Faculty of Medicine and Biomedical Sciences, University of Yaounde, Yaounde, Cameroon
- 6 Biohit, Helsinki, Finland
- 7 University Teaching Hospital, Yaounde, Yaounde, Cameroon
Abstract
Gastric colonization by Helicobacter pylori increases the risk of gastric disorders, including atrophic gastritis which can be diagnosed based on levels of serum biomarkers like Gastrin and Pepsinogen. We therefore examined the efficacy of a serological-based method namely GastroPanel Blood kit, in diagnosing and scoring gastritis associated to Helicobacter pylori infection. Patients with dyspeptic symptoms were prospectively recruited on voluntary basis at the Yaounde Central Hospital and University Teaching Hospital, from March to July 2011. The degree of atrophy was classified according to levels in patient serum of pepsinogens I and II (PGI and PGII) and Gastrin 17 (G17) and compared with histological profiles as reference method. A specific ELISA test was used for the detection of H. pylori IgG antibodies. In total, 86 volunteers from 21 to 83 years old (mean = 46.4 ± 3.3) were enrolled, including 74.4% of women and 25.6% of men. The prevalence of gastritis was statistically similar between Gastro Blood Panel test and histology used as reference method (89.5% versus 83.7%: p > 0.20). Diagnosis based on serum makers showed high sensitivity (93.1%) in comparison with the reference method. However, the serological based method has diagnosed more atrophic gastritis than the reference (17.4% versus 7.0%: p < 0.01), especially at antrum of stomach with H. pylori infection. The prevalence of H. pylori infection was 81.4% with histology versus 84.9% with serology (GBP) (p > 0.05). Furthermore, the prevalence of H. pylori infection did not differ significantly between serological method (84.9%) and reference method (81.4%). These results suggest that diagnosis of atrophic gastritis and H. pylori infection obtained with an optional serological method (GastroPanel) is in a strong agreement with the biopsy findings, and thus can be a useful non endoscopic assessment of stomach mucosal atrophy in patients with dyspepsia.
- Di Mario, F., Franzè, A. and Cavallaro, L.G. (2008) Non-invasive approach to diagnosis of upper gastroin- testinal diseases. AREA QUALITà S.r.l.
- Kokkola, A., Rautelin, H. and Puolakkainen, P. (1998) Positive result in serology indicates active Helicobacter pylori infection in patients with atrophic gastritis. Journal of Clinical Microbiology, 36, 1808-1810.
- Borody, T.J., Andrews, P., Jankiewicz, E., et al. (1993) Apparent reversal of early gastric mucosal atrophy after triple therapy for Helicobacter pylori. American Journal of Gastroenterology, 88, 1266-1268.
- WWW.biohit.com/diagnostics-servicelaboratory/March 2011
- www.biohit.com/gastropanel-gastropanel research applications/March 2011
- http://www.gastropanel.net/ http://www.biohit.com/Diagnostics/Litterature/March 2011
- Dixon, M.F., Genta, R.M. and Yardley, J.H. (1996) Classification and grading of gastritis. The updated Sydney system. American Journal of Pathology, 20, 1161-1181. doi:10.1097/00000478-199610000-00001
- Burtis, C.A. and Ashwood E.R. (1999) Text Book of Clinical Chemistry. 3rd Edition, 310-319.
- Sipponen, P., Harkonen, M. and Arto, A. (2001) Determination of atrophic gastritis from serum sample. Finnish medicine Journal, 38, 3833-3839.
- Pasechnikov, V.D., Sergey, C.Z., Sergey, M., et al. (2005) Invasive and non invasive diagnosis of Helicobacter pylori-associated atrophic gastritis: A comparative study. Scandinavian journal of Gastroenterology, 40, 297-301. doi:10.1080/00365520410010607
- Varis, K., Sipponen, P., Laxén, F., Samloff, M., Huttunen, J.K., Taylor, P.R., Heinonen, O.P., Albanes, D., Sande, N., Virtamo, J., H?rk?nen, M. and the Helsinki Gastritis Study Group (2000) Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Scandinavian Journal of Gastroenterology, 35, 950-956. doi:10.1080/003655200750023011
- Suovaniemi, O., Harkonen, M., Paloheimo, L. and Sipponen, P. (2003) GastroPanel: Diagnosing atrophic gastritis from serum providing a tool for evidence-based medicine, Business Briefing Global Health Care, 1-4. www.biohit.com
- Goedhard, J.G., Biemond, I., Gilians, J.P. and Pals, G. (1985) Serum pepsinogen I levels: assessment of gastric acid secretion. Progress Clinical and Biological Research, 173, 139-146.
- Massarrat S. (1985) Serum pepsin activity as a parameter of gastric acid secretion. Hepato-Gastroenterology, 32, 185-190.